ANI PHARMACEUTICALS, INC Finite-Lived Intangible Asset, Expected Amortization, Year One
ANI PHARMACEUTICALS, INC (ANIP) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $61.41 million as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-05-08
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $61.41M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $69.64M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $69.62M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $69.55M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-03-31 | $61.41M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $69.64M 10-K · filed 2026-02-27 |
| 2025-09-30 | $69.62M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $69.55M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $67.53M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $79.97M 10-K · filed 2025-02-28 |
| 2024-09-30 | $81.02M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $47.59M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $47.59M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $50.36M 10-K · filed 2024-02-29 |
| 2023-09-30 | $49.55M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $48.95M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $48.33M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $51.79M 10-K · filed 2023-03-09 |
| 2022-09-30 | $51.79M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $50.77M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $50.79M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $49.12M 10-K · filed 2022-03-15 |
| 2021-09-30 | $36.83M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $36.83M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $35.20M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $38.60M 10-K · filed 2021-03-11 |
| 2020-09-30 | $38.66M 10-Q · filed 2020-11-05 |
| 2014-12-31 | $4.49M 10-K · filed 2015-02-23 |
| 2013-12-31 | $996.00K 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |